NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Product Recall

Definition

Product recall is a process taken by the manufacturer, importer and wholesaler to remove or withdraw a particular products from all links of distribution.

The removal or withdrawal may be due to critical quality defects discovered or serious adverse drug reactions reported which might cause health risks to users of the products.


Decision For Recall

The decision for recall shall be made when there is or may caused potential risk to the user of the products by reason of faulty production or on medical grounds:

a) Voluntarily undertaken by the manufacturers and distributors.

b) As directed by the Director of Pharmaceutical Services, Ministry of Health.

Unless the Director of Pharmaceutical Services, Ministry of Health has already specified the degree and level of a particular products recall, the degree and level will be decided by the company’s Product Recall Committee based on risks involved. The Product Recall Committee shall comprise of personnel who are responsible for the execution and coordination of recall. The persons responsible shall handle all aspects of the recalls with the appropriate degree of urgency.

No recall shall take place without first consulting/informing the Authority.

Recalls that involve specific batch will not involve any other batch/batches that currently available in the market.

Not all recalls are initiated because a product is deemed unsafe or ineffective. A recall may also be conducted to remove products from the Malaysian market with quality defects that do not affect their safety and efficacy.

 

Degree of Recall

 

The degree of recall is classified according to the severity of quality defects and adverse reactions of the products.


Degree Definition Recall Notice by PRH
I Products with major health risks that might cause serious injuries or death. Should be under an embargo within 24 hours Within 24 hours of recall commencement or directive
II Products with minor health risks or are substandard. Should be under an embargo within 72 hours Within 48 hours of recall commencement or directive
III Products with other reasons for recall that can cause health risks to users. Should be under an embargo within 30 days or as specified Within 72 hours of recall commencement or directive
 

Level of Recall

The level of recall depends on the nature of problem, extent of the product’s distribution and degree of hazard involved.

Level A: To all consumers (end users).

Level B: To all points of sales (e.g. Hospitals, Pharmacies, Clinics, Specialist Centres).

Level C: To all sub-distributors (wholesalers).


Public Notification

Not all recalls are announced in press releases. However, when a product that has been widely distributed or poses a serious health hazard is recalled, NPRA may do so if the agency determines it is necessary to protect consumers.

 
References: 

1) Drug Registration Guidance Document (DRGD)

2) Guideline on Good Distribution Practice

 

Products as listed below have been recalled from the market.

Year 2026

 

No

Product Name

Registration Number

Active ingredients

Batch Number

Reason for Recall

Degree and Level of Recall

Registration Holder

Date of recall

1

Coredin Paediatric Linctus

MAL19880311AZ

  1. Ammonium Chloride
  2. Diphenhydramine Hydrochloride

19574, 19616

Precautionary measure following a complaint regarding the presence of particles confirmed to have originated from sugar crystallization in the product formulation.

Voluntary recall at the point of sub-distributor (wholesaler)

TERAPUTICS SDN BHD

30 January 2026

2

Vamlo Tablets 10mg 

MAL07010993AZ

Amlodipine 

24030132

Out of Trend (OOT) result for Related Substances “Impurity D” test at 18th month timepoint of stability study.

Voluntary recall up to the point of sales

RANBAXY (MALAYSIA) SDN. BHD.

13 February 2026

3

Doxycillin Tablet 100mg

MAL19860580AZ

Doxycycline Hydrochloride/ Hyclate

2403300, 2403301, 2405293

Out of specification result for related substance “Impurity C” test during the stability study.

Voluntary recall up to the point of sales

DUOPHARMA MANUFACTURING (BANGI) SDN. BHD.

19 February 2026

4

Uphamol Menstrual Tablet 500/25mg

MAL12025061X

  1. Paracetamol
  2. Pamabrom

2310222

Out-of-specification result was observed for the dissolution test during the stability study.

Voluntary recall up to the point of sales

Duopharma Marketing Sdn. Bhd.

9 February 2026

5

Gastrografin Aqueous Solution

MAL20001254ACRZ

  1. Amidotrizoic acid 
  2. Meglumine 

MA04LDV M1, MA04LDV M2, MA04MPS M1, MA04MPS M2

Precautionary measure following the detection of trace amounts of nitrosamine N-nitroso-meglumine above the acceptable intake limit in seven tested batches of the formulation without star anise oil. 

Voluntary recall up to the point of sales

Bayer Co. (Malaysia) Sdn. Bhd.

9 Mac 2026

6

Pro-Stisol Waist & Body Tonic Tablet

MAL16100054T

  1. Cornus officinalis
  2. Dioscorea opposita
  3. Radix Rehmanniae Glutinosa

013/2412 T22-004

The batch tested by NPRA had failed physical appearance test

Degree III recall up to the point of sales

Pro Stisol Manufacturing 

13 Mac 2026

7

Vitamode Astaxanthin Plus Glutathione Capsule

MAL15045003NC

  1. L-glutathione
  2. Haematococcus Pluvialis Extract

5NC10503

Product labelling on the blister strip found to be incorrect.

Voluntary recall up to the point of sales

Medispec (M) Sdn. Bhd.

16 Mac 2026

8

Axcel Mometasone 0.05%w/w Nasal Spray

MAL14025010AZ 

Mometasone Furoate 

B2509050, B2509050A, B2509064A

Out of Specification (OOS) for microbial limit test was detected during the stability study programme.

Voluntary recall up to all consumers level (end users)

Kotra Pharma (M) Sdn. Bhd.

10 April 2026

9

Glumet XR Tablet 500mg

MAL13015050AZ 

Metformin Hydrochloride 500mg 

5036723 

Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels.

Degree II recall up to the point of sales

Pharmaniaga Manufacturing Berhad 

15 April 2026

10

Glumet XR Tablet 750mg

MAL13025046AZ 

Metformin Hydrochloride 750mg 

5031724 

Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels.

Degree II recall up to the point of sales

Pharmaniaga Manufacturing Berhad 

15 April 2026

11

Glumet XR Tablet 500mg

MAL13015050AZ 

Metformin Hydrochloride 500mg 

5028486

5032332

5032334

2034104

5034103

5034100

5036722

5036724

5036723

5037167

5036983

5036984

5038424

5039549

5040444

Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels.

Voluntary recall up to the point of sales

Pharmaniaga Manufacturing Berhad 

14 May 2026

12

Glumet XR Tablet 750mg 

MAL13025046AZ 

Metformin Hydrochloride 750mg 

5029183

5030138

5030777

5030778

5030779

5031726

5031728

5031724

5032581

5032577

5033837

5034636

5035512

5035844

5037253

5040469

Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels.

Voluntary recall up to the point of sales

Pharmaniaga Manufacturing Berhad 

14 May 2026

13

Apalin 250mg Injection (2ml Amp)

MAL19984033AZ 

Amikacin Sulphate

242837T 



The batch tested by NPRA had failed sterility test

Degree I recall up to the point of sales

Duopharma (M) Sdn. Bhd 

14 May 2026

14

Vegesamine Capsule 500mg

MAL08111949XR 

Glucosamine HCl 

1770600A (182/AO), 1770600A (182/AO), 1770600A (182/AO), 1770600A (182/AP), 1770600A (182/AP), 1770600A (182/AP), 698300 (182/AQ), 698300 (182/AQ) 

This recall is being conducted because the product registration has expired on 7th December 2025 and exemption

period for marketing purpose is coming to an end on 6th June 2026.

Voluntary recall up to the point of sales

21st Century Products Sdn. Bhd. 

20 May 2026

15

Nature's Green Ying Nin Tablets

MAL14105008T 

Multiple active ingredients

2505311 

The batch tested by NPRA had failed physical appearance test.

Degree III recall up to the point of sales

Tong Jum Chew (M) Sdn. Bhd. 

15 June 2026

16

NutrinLife Man Pro Capsule 

MAL19036043NCR 

  1. Serenoa Repens Berry Extract (Saw Palmetto)
  2. Zinc Oxide

H09823310 

Out of Specification result was observed for zinc content (ICP-OES).

Voluntary recall up to the point of sales

Biofunction Marketing Sdn. Bhd 

19 June 2026

17

Doxycillin Tablet 100mg

MAL19860580AZ

Doxycycline Hydrochloride

2410251, 2410252, 2410253, 2410254

2503230, 2503231, 2503232

Out of Specification (OOS) for Related Substances (Impurity F test) was detected during batch monitoring

following a previous product recall exercise.

Voluntary recall up to the point of sales

Duopharma Manufacturing (Bangi) Sdn. Bhd.

25 June 2026

18

Decondine Syrup 

MAL19860261AZ 

  1. Triprolidine Hydrochloride
  2. Pseudoephedrine Hydrochloride

307-24002, 307-24003, 307-24004, 307-24005, 307-24008, 307-24009, 307-24010, 307-24011, 307-24012, 307-24013 

Precautionary measure following the out-of-specification result was observed for the assay test (Triprolidine HCL) for batch 307-22007

at the 30-month stability study time point, which is near the end of the product’s shelf life.

Voluntary recall at the point of sub-distributor (wholesaler)

Sunward Pharmaceutical Sdn. Bhd.

3 July 2026

19

Idaman Pharma Enalapril Tablet 5mg

MAL23116014AZ 

Enalapril Maleate

5034698 

Out of Specification result was observed for dissolution test at 18 month timepoint stability testing.

Voluntary recall up to the point of sales

Inspirapharma Sdn. Bhd. 

8 July 2026

20

Lanzotred soft capsules (Enzalutamide Soft capsules 40 mg)

MAL22096035AZ

Enzalutamide 

F10753P2 & G19850P2

Out of Specification result was observed for the impurity Enzalutamide Dioxoimidazolidine.

Voluntary recall up to the point of sales

Dr. Reddy`s Laboratories Malaysia Sdn. Bhd.

3 August 2026

21

TSART 40 (Telmisartan Tablets USP 40mg)

MAL19056110AZ

Telmisartan

25142819

Out of Specification result was observed for the product description at 9th months stability time point. 

Voluntary recall at the point of sub-distributor (wholesaler)

Ascend Laboratories Sdn. Bhd.

4 August 2026

Last updated 07/08/2026

Year 2025
Year 2024
Year 2023

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 14 August 2026, 15:56:35.

Search

Main Menu English